AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Recombinant Tuberculosis BCG Vaccine Elicits a Highly Protective Host Immune Response

Technology Benefits

Directs a hosts immune response towards a more potent protective immune response. More efficacious than the currently available vaccine and even rBCG30, which itself is more potent than the currently available vaccine.

Technology Application

A more potent and effective vaccine against TB.

Detailed Technology Description

UCLA researchers have developed an improved version of the rBCG30 vaccine that co-expresses host immunostimulatory molecules that shift the hosts immune response towards a more protective type of immune response. These vaccines are significantly more potent than the first generation rBCG30 vaccine in the highly relevant and stringent outbred guinea pig model of pulmonary tuberculosis, a model that closely mimics human tuberculosis.

Supplementary Information

Patent Number: US8287879B2
Application Number: US2008296666A
Inventor: Horwitz, Marcus A. | Harth, Gunter
Priority Date: 16 Oct 2003
Priority Number: US8287879B2
Application Date: 9 Oct 2008
Publication Date: 16 Oct 2012
IPC Current: A61K003902 | A61K003904 | A61K004500 | A61K004700
US Class: 4242001 | 4242341 | 4242481 | 4242781
Assignee Applicant: The Regents of the University of California
Title: Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
Usefulness: Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
Summary: The immunogenic composition comprising a recombinant Bacille Calmette Guerin (rBCG) expressing at least one Mycobacteria major extracellular protein is useful as vaccine against pathogenic bacteria, e.g., Mycobacterium bovis .
Novelty: New immunogenic composition comprising a recombinant Bacille Calmette Guerin (rBCG) expressing at least one Mycobacteria major extracellular protein, useful as vaccine against pathogenic bacteria, e.g., Mycobacterium bovis

Industry

Biomedical

Sub Group

Pathogen

Application No.

8287879

Others

State of Development

This vaccine has been tested and proven effective in guinea pigs.

Background

The only currently available TB vaccine, an attenuated Mycobacterium bovis strain Bacille Calmette-Guerin (BCG), is of variable efficacy. A large carefully conducted meta-analysis has estimated the potency of BCG to be approximately 50%. UCLA researchers developed and reported in the last several years a recombinant BCG expressing the Mycobacterium tuberculosis 30 kDa major secretory protein (r30). This vaccine, named rBCG30, induces greater protection than BCG against aerosol challenge with a highly virulent strain of M. tuberculosis.

Additional Technologies by these Inventors

Tech ID/UC Case

20146/2006-538-0

Related Cases

2006-538-0

Country/Region

USA

For more information, please click Here